Concept Medical Unveils Three-Year SIRONA Trial Results at Charing Cross Symposium 2026

On April 27, 2026, Concept Medical Inc. made a significant announcement concerning the preliminary three-year follow-up data from the SIRONA randomized trial. This presentation took place during the Charing Cross (CX) Symposium 2026, signaling Concept Medical's cutting-edge position in drug-delivery technologies aimed at enhancing peripheral interventions.

The SIRONA trial evaluates the efficacy of sirolimus-coated balloons in comparison to the traditional paclitaxel-coated balloons in treating femoropopliteal artery disease. This important study seeks to provide solid comparative evidence in a sector that has predominantly relied on paclitaxel-based therapies. Previous reports published in the Journal of the American College of Cardiology (JACC) showcased promising 12-month outcomes, illustrating the non-inferiority of the sirolimus-coated approach on key efficacy and safety metrics.

During this latest analysis, it was revealed that the MagicTouch PTA – Concept Medical's sirolimus-coated balloon – offered a noteworthy advantage, demonstrating an 88.2% freedom from clinically driven target lesion revascularization (cdTLR), surpassing the 80.2% observed in the paclitaxel-coated group (HR 0.60; 95% CI 0.36–0.97; log-rank p=0.03). The final validation of these results awaits the assessment by the Clinical Events Committee (CEC).

The findings portray a compelling narrative suggesting that sirolimus-coated balloons might ensure more sustainable long-term solutions compared to their paclitaxel counterparts. At the three-year mark, rates of all-cause mortality were found to be comparable across both treatment factions (92.6% vs. 92.6%; HR 1.12; p=0.67), further supporting the long-term safety profile of the treatment. Moreover, major amputation rates showed minimal correspondence, demonstrating similar outcomes across both groups (99.6% vs. 99.6%; HR 0.54; p=0.61).

Prof. Ulf Teichgräber, the Principal Investigator overseeing the trial, expressed enthusiasm regarding the preliminary results, noting, "These initial three-year findings are indeed promising. The sustained reduction in cdTLR with MagicTouch PTA across such an extended follow-up period is highly encouraging, validating the robustness of sirolimus-based drug delivery in femoropopliteal interventions."

Alongside, Dr. Manish Doshi, the founder and Managing Director at Concept Medical, highlighted the importance of long-term clinical inquiry within the SIRONA trial ethos, asserting, "We aim to go beyond early outcomes and genuinely grasp durability. These three-year results reinforce the comparative efficacy of sirolimus-coated balloons, a crucial aspect as we expand our global footprint."

Concept Medical’s headquarters is located in Florida, USA, with additional manufacturing sites in India. Its proprietary Nanolute™ technology platform is designed to enable the precise and sustained delivery of sirolimus, not just in coronary applications, but in peripheral contexts as well. The company’s flagship product, MagicTouch, is acknowledged internationally as one of the most extensively researched sirolimus-coated balloon platforms available.

In conclusion, the preliminary findings of the SIRONA trial presented at the Charing Cross Symposium 2026 herald a new chapter in peripheral artery disease management, suggesting that personalized approaches guided by robust clinical evidence are pivotal for optimizing patient outcomes. As the medical community awaits further validations following CEC adjudication, these promising results could redefine therapeutic choices in the realm of peripheral artery interventions.